Derived

Development pipeline · Malignant Testicular Neoplasm

For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.

Computedci-drug-pipeline-v1Stage rules Approvals feed →

Top-level cancerStageClear

Funnel

67 drugs by highest stage

Drugs reach Malignant Testicular Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.

Phase 1
8 drugs · 0 active trials
Alisertib, Bevacizumab, Cediranib, Guadecitabine, HDAC Inhibitor REC-2282
Phase 2
30 drugs · 6 active trials
Ipilimumab, Paclitaxel, Veliparib, Aspirin, Nivolumab
Phase 3

21 drugs · 23 active trials

Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin, Methotrexate

Phase 4

0 drugs · 0 active trials

no drug at this stage

Approved

3 drugs · 2 active trials

Etoposide, Ifosfamide, Dactinomycin

Outside the funnel: Phase not stated 5. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.

Computedclinicaltrialsemahealth-canada-dpdopenfdaci-drug-pipeline-v1

Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer

Drugs

0 phase 4 drugs · Malignant Testicular Neoplasm

Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).

Data not yet available

No drug at this stage for the selected scope.

Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.